

Notice: Archived Document

The content in this document is provided on the FDA's website for reference purposes only. This content has not been altered or updated since it was archived.

Reproducibility of Oral Abuse Liability Studies

Primary endpoints drug disliking	Study 102	Study 111	Study 114
Scale	Unipolar: NRS	Bipolar: NRS	Bipolar: VAS
Range	1-29	1-29	0-100
LSMean Differences (SE) 40/240 mg vs. 40/0 mg	5.1 (2.4) p = 0.05	-3.0 (1.4) p = 0.033	-18.7 (3.12) p <0.0001